+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis

  • ID: 5265141
  • Report
  • February 2021
  • Region: Global
  • Renub Research
Allergic Conjunctivitis Market will be US$ 2,783.5 Million by 2027

FEATURED COMPANIES

  • Alcon (Novartis)
  • Ocular Therapeutix
  • Portola Pharmaceuticals
  • Santen Pharmaceutical
  • MORE
Allergic conjunctivitis is common ophthalmic disorder caused by reactions to allergens like pollen or mold spores, dust mites and animal fur. The eyeball has a membrane called conjunctiva which is receptive towards the irritation from allergens.



In July 2020, IACTA Pharmaceuticals & Zhaoke Ophthalmology Pharmaceuticals Ltd has signed an agreement to accelerate the development of drugs called IC265 and IC 270. Earlier they were develop to treat dry eye and later for allergic conjunctivitis.

There are many types of allergic conjunctivitis such as seasonal allergic conjunctivitis is caused by airborne mold spores, spring, late summer, or early fall and disappear during the winter month & perennial allergic conjunctivitis is caused by dust, mites, animal dander, and other non-seasonal allergens.

According to this research, Allergic Conjunctivitis Market was US$ 1.5 Billion in 2020 is expected to grow with a CAGR of 8.81% and reach US$ 2.7 Billion by 2027.

There has been significant increase allergic conjunctivitis due to increase in the use of chemicals and pollution caused by urbanization, industrialization and climate change. The increase in awareness of allergic conjunctivitis is associated its medical treatment & upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. is one of the factors driving the market.

Many Pharmaceutical companies are trying to develop many new possibilities of treatment for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC’s EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials.

The publisher has studied by region of North America followed by Europe and Asia-Pacific. The allergic conjunctivitis treatment market in Asia Pacific is expected to grow rapidly, due to having a large population base and increased demand of improved health facilities.

This report titled “Global Allergic Conjunctivitis Market, Patients, Treated Patients By Countries (India, China, Japan, United States, United Kingdom, France, Germany, Italy, Spain), Disease Type (Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Kerato Conjunctivitis (VKC), Atopic Kerato Conjunctivitis (AKC) And Giant Papillary Conjunctivitis (GPC)), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011) Companies (Santen Pharmaceutical, Alcon (Novartis), Portola Pharmaceuticals, Ocular Therapeutix), Growth Drivers, Challenges” provides a complete analysis of global allergic conjunctivitis market.

Global Allergic Conjunctivitis Market has been analyzed from 9 Major Viewpoints
  • Market - Global Allergic Conjunctivitis
  • Market Share, Disease Type Market Share, Patients Share, Treated Patients Share
  • Market - Country Allergic Conjunctivitis
  • Patients Population - Country Allergic Conjunctivitis
  • Country Allergic Conjunctivitis Treated Patients Population
  • Disease Type - Allergic Conjunctivitis Market
  • Drugs Pipeline - Allergic Conjunctivitis
  • Key Growth factors and Challenges
  • Key Companies Initiatives and Financial Insights
Country - Market breakup from 9 viewpoints
  • India
  • China
  • Japan
  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
Disease - Market Breakup from 4 viewpoints
  • Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
  • Vernal Kerato Conjunctivitis (VKC)
  • Atopic Kerato Conjunctivitis (AKC)
  • Giant Papillary Conjunctivitis (GPC)
Drugs - Market Breakup from 10 viewpoints
  • Zerviate
  • OTX-DP
  • ADX-102
  • PRT-2761
  • CVXL-0074
  • AK-002
  • Bertilimumab
  • Reproxalap
  • ST-266
  • SYL-116011
All companies has been covered from 3 viewpoints
  • Overviews
  • Recent Developments
  • Revenues
Company Covered
  • Santen Pharmaceutical
  • Alcon (Novartis)
  • Portola Pharmaceuticals
  • Ocular Therapeutix
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alcon (Novartis)
  • Ocular Therapeutix
  • Portola Pharmaceuticals
  • Santen Pharmaceutical
  • MORE
1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Global Allergic Conjunctivitis Market and Patients Analysis
5.1 Market
5.2 Patient Numbers
5.3 Treated Patient Numbers

6. Share Analysis - Global Allergic Conjunctivitis
6.1 Country Market Share
6.2 Patients Population Share
6.3 Treated Patients Population Share
6.4 By Disease Type Share

7. India - Allergic Conjunctivitis Analysis
7.1 Patient Numbers
7.2 Treated Patient Numbers
7.3 Market

8. China - Allergic Conjunctivitis Analysis
8.1 Patient Numbers
8.2 Treated Patient Numbers
8.3 Market

9. Japan - Allergic Conjunctivitis Analysis
9.1 Patient Numbers
9.2 Treated Patient Numbers
9.3 Market

10. United States - Allergic Conjunctivitis Analysis
10.1 Patient Numbers
10.2 Treated Patient Numbers
10.3 Market

11. United Kingdom - Allergic Conjunctivitis Analysis
11.1 Patient Number
11.2 Treated Patient Numbers
11.3 Market

12. France - Allergic Conjunctivitis Analysis
12.1 Patient Numbers
12.2 Treated Patient Numbers
12.3 Market

13. Germany - Allergic Conjunctivitis Analysis
13.1 Patient Numbers
13.2 Treated Patient Numbers
13.3 Market

14. Italy - Allergic Conjunctivitis Analysis
14.1 Patient Numbers
14.2 Treated Patient Numbers
14.3 Market

15. Spain - Allergic Conjunctivitis Analysis
15.1 Patient Numbers
15.2 Treated Patient Numbers
15.3 Market

16. Disease Type - Global Allergic Conjunctivitis Market
16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
16.2 Vernal Keratoconjunctivitis (VKC)
16.3 Atopic Keratoconjunctivitis (AKC)
16.4 Giant Papillary Conjunctivitis (GPC)

17. Global Allergic Conjunctivitis Pipeline Drugs
17.1 Zerviate
17.2 OTX-DP (Dexamethasone Insert)
17.3 ADX-102
17.4 PRT2761
17.5 CVXL-0074
17.6 AK-002
17.7 Bertilimumab
17.8 Reproxalap
17.9 ST-266
17.10 SYL-116011

18. Company Analysis
18.1 Santen Pharmaceutical
18.1.1 Company Overview
18.1.2 Recent Developments
18.1.3 Financial Insight
18.2 Alcon Inc. (Novartis)
18.2.1 Company Overview
18.2.2 Recent Developments
18.2.3 Financial Insight
18.3 Portola Pharmaceuticals Inc.
18.3.1 Company Overview
18.3.2 Recent Developments
18.3.3 Financial Insight
18.4 Ocular Therapeutix Inc.
18.4.1 Company Overview
18.4.2 Recent Developments
18.4.3 Financial Insight

List of Figures:
Figure 2-1: Global - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 2-2: Global - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 2-3: Global - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 2-4: Global - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 2-5: Global - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 2-6: Global - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 3-1: Global - Allergic Conjunctivitis Market Country Share (Percent), 2016 - 2020
Figure 3-2: Global - Forecast for Allergic Conjunctivitis Market Country Share (Percent), 2021 - 2027
Figure 3-3: Global - Allergic Conjunctivitis Treated Patients Population Country Share (Percent), 2016 - 2020
Figure 3-4: Global - Forecast for Allergic Conjunctivitis Treated Patients Population Country Share (Percent), 2021 - 2027
Figure 3-5: Global - Allergic Conjunctivitis Disease Type Market Share (Percent), 2016 - 2020
Figure 3-6: Global - Forecast for Allergic Conjunctivitis Disease Type Market Share (Percent), 2021 - 2027
Figure 4-1: India - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 4-2: India - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 4-3: India - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 4-4: India - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 4-5: India - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 4-6: India - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 5-1: China - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 5-2: China - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 5-3: China - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 5-4: China - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 5-5: China - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 5-6: China - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 6-1: Japan - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 6-2: Japan - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 6-3: Japan - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 6-4: Japan - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 - 2025
Figure 6-5: Japan - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 6-6: Japan - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 7-1: United States - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 7-2: United States - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 7-3: United States - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 7-4: United States - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 7-5: United States - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 7-6: United States - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 8-1: United Kingdom - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 8-2: United Kingdom - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 8-3: United Kingdom - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 8-4: United Kingdom - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 8-5: United Kingdom - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 8-6: United Kingdom - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 9-1: France - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 9-2: France - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 9-3: France - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 9-4: France - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 9-5: France - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 9-6: France - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 10-1: Germany - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 10-2: Germany - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 10-3: Germany - Allergic Conjunctivitis Patient Treated Numbers (Million), 2016 - 2020
Figure 10-4: Germany - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 10-5: Germany - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 10-6: Germany - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 11-1: Italy - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 11-2: Italy - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 11-3: Italy - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 11-4: Italy - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 11-5: Italy - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 11-6: Italy - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 12-1: Spain - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2020
Figure 12-2: Spain - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2021 - 2027
Figure 12-3: Spain - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2020
Figure 12-4: Spain - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2021 - 2027
Figure 12-5: Spain - Allergic Conjunctivitis Market (Million US$), 2016 - 2020
Figure 12-6: Spain - Forecast for Allergic Conjunctivitis Market (Million US$), 2021 - 2027
Figure 13-1: Global - Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2016 - 2020
Figure 13-2: Global - Forecast for Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2021 - 2027
Figure 13-3: Global - Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2016 - 2020
Figure 13-4: Global - Forecast for Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2021 - 2027
Figure 13-5: Global - Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2016 - 2020
Figure 13-6: Global - Forecast for Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2021 - 2027
Figure 13-7: Global - Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2016 - 2020
Figure 13-8: Global - Forecast for Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2021 - 2027
Figure 14-1: Allergic Conjunctivitis Pipe Line Drug - Zerviate Status (2018)
Figure 14-2: Allergic Conjunctivitis Pipe Line Drug - OTX-DP (Dexamethasone Insert) Status (2018)
Figure 14-3: Allergic Conjunctivitis Pipe Line Drug - ADX-102 Status (2018)
Figure 14-4: Allergic Conjunctivitis Pipe Line Drug - PRT-2761Status (2018)
Figure 14-5: Allergic Conjunctivitis Pipe Line Drug - CVXL-0074 Status (2018)
Figure 14-6: Allergic Conjunctivitis Pipe Line Drug - AK-002 Status (2018)
Figure 14-7: Allergic Conjunctivitis Pipe Line Drug - Bertilimumab Status (2018)
Figure 14-8: Allergic Conjunctivitis Pipe Line Drug - Reproxalap Status (2018)
Figure 14-9: Allergic Conjunctivitis Pipe Line Drug - ST-266 Status (2018)
Figure 14-10: Allergic Conjunctivitis Pipe Line Drug - SYL-116011 Status (2018)
Figure 17-1: Santen Pharmaceutical - Global Revenue (Million US$), 2016 - 2020
Figure 17-2: Santen Pharmaceutical - Forecast for Global Revenue (Million US$), 2021 - 2027
Figure 18-1: Alcon (Novartis) - Global Revenue (Million US$), 2016 - 2020
Figure 18-2: Alcon (Novartis) - Forecast for Global Revenue (Million US$), 2021 - 2027
Figure 19-1: Portola Pharmaceuticals - Global Revenue (Thousand US$), 2016 - 2020
Figure 19-2: Portola Pharmaceuticals - Forecast for Global Revenue (Thousand US$), 2021 - 2027
Figure 20-1: Ocular Therapeutix - Global Revenue (Thousand US$), 2016 - 2020
Figure 20-2: Ocular Therapeutix - Forecast for Global Revenue (Thousand US$), 2021 - 2027
Figure 21-1: Novartis - Global Revenue (Million US$), 2016 - 2020
Figure 21-2: Novartis - Forecast for Global Revenue (Thousand US$), 2021 - 2027

List of Tables:
Table 3-1: Global - Allergic Conjunctivitis Patients Population Country Share (Percent), 2016 - 2020
Table 3-2: Global - Forecast for Allergic Conjunctivitis Patients Population Country Share (Percent), 2021 - 2027
Note: Product cover images may vary from those shown
  • Santen Pharmaceutical
  • Alcon (Novartis)
  • Portola Pharmaceuticals
  • Ocular Therapeutix
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll